An overview of the efficacy and safety of CGRP pathway therapies in migraine prevention
Migraine is the most prevalent neurological disorder worldwide1 and, recently, blocking the calcitonin gene-related pathway (CGRP) has emerged as a target for migraine prevention.1 As part of the “Targeting CGRP for migraine prevention. What is new?” session at the 7th Congress of the European Academy of Neurology (EAN), Dr. Anna Andreou (King’s College L
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now